S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Mine OK'd in Trump's last days may boost Biden energy plan
pixel
DuPont, Chemours reach agreement over 'forever chemicals'
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
pixel
The Latest: Short on bed space, Brazilian state locks down
The Latest: Court rules against S. Calif. church request
Normal diets for trapped China miners as rescue continues
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Mine OK'd in Trump's last days may boost Biden energy plan
pixel
DuPont, Chemours reach agreement over 'forever chemicals'
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
pixel
The Latest: Short on bed space, Brazilian state locks down
The Latest: Court rules against S. Calif. church request
Normal diets for trapped China miners as rescue continues
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Mine OK'd in Trump's last days may boost Biden energy plan
pixel
DuPont, Chemours reach agreement over 'forever chemicals'
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
pixel
The Latest: Short on bed space, Brazilian state locks down
The Latest: Court rules against S. Calif. church request
Normal diets for trapped China miners as rescue continues
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Mine OK'd in Trump's last days may boost Biden energy plan
pixel
DuPont, Chemours reach agreement over 'forever chemicals'
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
pixel
The Latest: Short on bed space, Brazilian state locks down
The Latest: Court rules against S. Calif. church request
Normal diets for trapped China miners as rescue continues
Log in
ASX:BGT

Bio-Gene Technology Limited (BGT.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.19
MA: A$0.19▼
A$0.19
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has collaborations with Pacific Discovery Services for studying Flavocide's mode of action; and the Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

MarketRank™

Overall MarketRank™

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:BGT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.bio-gene.com.au
Phone61 3 9628 4178
EmployeesN/A

Debt

Debt-to-Equity Ratio0.19
Current Ratio15.00
Quick Ratio14.58

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$122,795.00
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow7.04
Book ValueA$0.04 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive BGT News and Ratings via Email

Sign-up to receive the latest news and ratings for BGT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Gene Technology Limited (BGT.AX) (ASX:BGT) Frequently Asked Questions

What stocks does MarketBeat like better than Bio-Gene Technology Limited (BGT.AX)?

Wall Street analysts have given Bio-Gene Technology Limited (BGT.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Gene Technology Limited (BGT.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Bio-Gene Technology Limited (BGT.AX)'s key competitors?

Some companies that are related to Bio-Gene Technology Limited (BGT.AX) include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB) and Algernon Pharmaceuticals (AGNPF).
View all of BGT's competitors.

Who are Bio-Gene Technology Limited (BGT.AX)'s key executives?

Bio-Gene Technology Limited (BGT.AX)'s management team includes the following people:
  • Mr. Richard Jagger B.Sc., BSC (HONS), M.INTL.BUS, GAICD, MD, CEO & Director
  • Mr. Roger McPherson C.P.A., CPA, B.Bus, GAICD, CFO & Company Sec.
  • Mr. Peter Donald May AFAIM, M.B.A., MBA, AFA1M, GAICD, Exec. Director of R&D and Exec. Director

What is Bio-Gene Technology Limited (BGT.AX)'s stock symbol?

Bio-Gene Technology Limited (BGT.AX) trades on the ASX under the ticker symbol "BGT."

How big of a company is Bio-Gene Technology Limited (BGT.AX)?

Bio-Gene Technology Limited (BGT.AX) has a market capitalization of $0.00 and generates $122,795.00 in revenue each year.

What is Bio-Gene Technology Limited (BGT.AX)'s official website?

The official website for Bio-Gene Technology Limited (BGT.AX) is www.bio-gene.com.au.

How can I contact Bio-Gene Technology Limited (BGT.AX)?

The company can be reached via phone at 61 3 9628 4178.

This page was last updated on 1/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.